Funding for Risky Biotechs Is Returning

2026-01-12 | original

read original get NeuroPace → more articles

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

Explore topics: billion billion shares developers developers sold drug